In our current study, we found that HER2‐low breast cancer patients had similar clinicopathological parameters with HER2‐0 rather than HER2‐positive cases, had relatively low sTILs, and had significantly inferior survival in the ER‐negative subgroup. The gene discussed is ESR1; the disease is breast carcinoma.